The current model for translation initiation proposes that translation initiation factor 2 (eIF2) forms a ternary complex with GTP and charged initiator tRNA Met , which binds to 40S ribosomes. After mRNA binding to the ribosome and recognition of the AUG codon by initiator tRNA Met , GTP hydrolysis releases an eIF2 ⅐ GDP binary complex. For eIF2 to participate in further rounds of initiation, it must be recycled to eIF2 ⅐ GTP by the guanine nucleotide exchange factor eIF2B. This recycling of eIF2 ⅐ GDP to eIF2 ⅐ GTP by eIF2B is inhibited by phosphorylation of eIF2 on its ␣ subunit (eIF2␣) at serine 51 (reviewed in references 30 and 44) . Three protein kinases, known as HRI, PKR, and GCN2, specifically phosphorylate Ser-51 of eIF2␣ under different stress conditions (12, 48) . HRI is activated in mammalian reticulocytes in response to heme deprivation, whereas PKR (also known as DAI or p68 kinase) is part of the antiviral response and is activated by double-stranded RNA. Both kinases phosphorylate eIF2 to shut off total protein synthesis by complete inhibition of eIF2B.
In the yeast Saccharomyces cerevisiae, GCN2 phosphorylates eIF2 in response to starvation for amino acids or purines. The level of eIF2 phosphorylated on its ␣ subunit [eIF2(␣P)] produced by moderate starvation in yeast cells is not sufficient to inhibit total protein synthesis; however, it does result in a specific increase in translation of GCN4 mRNA, encoding a transcriptional activator of amino acid biosynthetic genes (reviewed in reference 23). Thus, translation of GCN4 is inversely coupled to the concentration of eIF2 ⅐ GTP ⅐ tRNA i
Met ternary complexes and, therefore, to the catalytic activity of eIF2B. Mutationally activated forms of GCN2 that generate higher levels of eIF2(␣P) than are seen in nutrient-deprived cells have been isolated (35, 51) , and in these GCN2 c mutants, or in yeast cells expressing human PKR or HRI (15) , general translation initiation and cellular growth are greatly inhibited.
Strong genetic evidence supports the model that phosphorylation of eIF2␣ on Ser-51 regulates translation initiation in yeast by inhibiting eIF2B function, just as in mammalian cells. All five subunits of eIF2B, encoded by GCN3, GCD7, GCD1, GCD2, and GCD6 (equivalent to the mammalian polypeptides ␣ to ε, respectively), were first identified genetically as regulators of GCN4 translation (21) . The GCD genes encoding eIF2B subunits are essential, and nonlethal mutations in each result in constitutive high-level translation of GCN4 (Gcd Ϫ phenotype) and reduced cellular growth rates on nutrient-rich media. Presumably, these gcd mutations lead to decreased ternary complex concentrations independently of eIF2 phosphorylation by impairing eIF2B structure or catalytic activity. In contrast, the GCN3 subunit of eIF2B is dispensable, and its inactivation impairs only the ability to stimulate GCN4 translation under starvation conditions (19, 24) . This is the same Gcn Ϫ phenotype observed following inactivation of the protein kinase GCN2 or replacement of Ser-51 in eIF2␣ with nonphosphorylatable alanine (16) . Therefore, it was proposed that GCN3 is a regulatory subunit required to mediate the inhibitory effect of eIF2(␣P) on eIF2B function (15) . It was shown recently that the effects of eIF2 phosphorylation on GCN4-specific and general translation initiation are reduced by overproducing all five subunits of eIF2B or, even more effectively, by overexpressing just a four-subunit complex containing the essential subunits GCD7, GCD1, GCD2, and GCD6 (17) . These results confirmed that eIF2B function is impaired in yeast cells when eIF2 is hyperphosphorylated on Ser-51, and they lent further support to the idea that GCN3 makes eIF2B more sensitive to inhibition by eIF2(␣P).
Biochemical studies with mammalian systems have shown that eIF2(␣P) ⅐ GDP is an inhibitor that binds to eIF2B and interferes with the recycling of nonphosphorylated eIF2. This causes complete inhibition of protein synthesis even when only a fraction of eIF2 is phosphorylated. One proposed mechanism suggests that dissociation of the eIF2B ⅐ eIF2(␣P) ⅐ GDP complex is extremely slow, such that eIF2B is, in effect, bound irreversibly by phosphorylated eIF2. Because eIF2 is in a considerable excess with respect to eIF2B, phosphorylation of only a small fraction of eIF2 would be sufficient to sequester all of the eIF2B in inactive complexes. An alternative model suggests that eIF2(␣P) has a much greater rate of association with eIF2B than does nonphosphorylated eIF2, allowing eIF2(␣P) to act as a competitive inhibitor without forming an excessively stable eIF2B ⅐ eIF2(␣P) ⅐ GDP complex. The latter hypothesis is consistent with biochemical studies by Rowlands et al. (39) , using highly purified mammalian eIF2 and eIF2B, and with the in vivo effects of overproducing eIF2 in yeast cells containing an activated eIF2␣ kinase (17) . However, little is known at the molecular level about how eIF2 phosphorylation affects its affinity for eIF2B or inhibits nucleotide exchange. eIF2B is atypical of guanine nucleotide exchange factors in containing so many subunits. For example, the exchange factor for RAS in Saccharomyces is the single polypeptide encoded by CDC25 (4) . The subunit complexity of eIF2B could reflect its regulation by phosphorylated eIF2, and the fact that GCN3 is required primarily for inhibition by eIF2(␣P) is in accord with this idea. Genetic evidence suggests that GCD7 and GCD2 also have roles in this regulatory mechanism. First, GCN3, GCD7, and the C-terminal half of GCD2 have sequence similarity with each other (Fig. 1) (5) . Also, four point mutations in GCD7 and a single mutation in GCD2 were isolated in a random screen for mutations that mimic deletion of GCN3 by reversing the toxicity of eIF2 hyperphosphorylation on cell growth ( Fig. 1) (47) . As expected, many GCN3 mutations were also obtained in this screen; however, no mutations in GCD1 or GCD6 were isolated. These results led to the idea that GCD2, GCD7, and GCN3 have important functions in the regulation of eIF2B activity, whereas GCD1 and GCD6 could be involved principally in catalysis (22) . We recently obtained biochemical evidence to support this view by showing that overexpression of GCD2, GCD7, and GCN3 leads to the formation of a stable subcomplex containing only these three subunits of eIF2B. Overexpression of this trimeric subcomplex partially suppressed the toxicity of eIF2 phosphorylation without increasing the catalytic activity of eIF2B, presumably by sequestering eIF2(␣P) and allowing native eIF2B to exchange the nonphosphorylated eIF2 (52) . These results support the idea that GCD2, GCD7, and GCN3 form a regulatory domain in eIF2B that interacts with eIF2(␣P).
To test our hypothesis that GCD2 plays an important role in the regulation of eIF2B by eIF2(␣P) and to identify residues in GCD2 critical for this function, we set out to isolate GCD2 mutations that render eIF2B insensitive to eIF2(␣P) without reducing the catalytic activity of the recycling factor. We isolated nine regulatory mutations that, in agreement with our model, alter residues only in the C-terminal half of GCD2, which has sequence similarity with GCD7 and GCN3. Interestingly, the GCD2 mutations and additional regulatory mutations that we isolated subsequently in GCD7 and GCN3 cluster in two segments of ca. 70 residues in length, both of which are within the region of sequence similarity. Moreover, in several instances we recovered mutations that alter homologous positions in two or all three of the subunits. These results imply that structurally related segments in GCD2, GCD7, and GCN3 are devoted to the regulatory interactions between eIF2B and eIF2. We propose that these three subunits employ homologous structural elements to form a single regulatory domain on eIF2B, in which each subunit makes independent contacts with eIF2␣ at points surrounding the phosphorylation site at Ser-51. This structural organization would enable eIF2B to assess the phosphorylation state of bound eIF2. The mutations described here would disrupt one of these interactions with eIF2␣ or alter the interplay between eIF2B subunits, so that eIF2B fails to discriminate between eIF2 and eIF2(␣P) and allows nucleotide exchange on the phosphorylated substrate.
MATERIALS AND METHODS

Plasmids.
The following plasmids were constructed previously: (i) derivatives of the single-copy CEN4 URA3 plasmid YCp50 (37) bearing GCN3 (Ep69) (19) or gcn2-507 (p591) (50); (ii) derivatives of the low-copy-number CEN6 URA3 plasmid pRS316 (42) (35) , SUI2 (encoding eIF2␣) (p919) (16) , or GCD7 (pJB99) (5); (iii) high-copy-number 2m URA3 plasmids with a GAL-CYC promoter driving expression of the cDNAs encoding wild-type PKR (p1420) or the catalytically defective mutant PKR-K296R (p1421) (15) ; (iv) the high-copy-number 2m URA3 GCD2 plasmid pCP57 (6); (v) derivatives of the low-copy-number CEN6 LEU2 plasmid pRS315 (42) containing GCD7 (p1305 and p1558), GCD7-1118T (p1559), GCD7-D178Y (p1560), GCD7-K329E (p1561), GCD7-1348V (p1562), or GCD7-1118T,D178Y (p1563) (47); (vi) the low-copy-number LEU2 CEN4, plasmids bearing SUI2 (p1097), SUI2-S51A (p1098), SUI2-S51D (p1101) (16) , and SUI2-L84F (p1350) (46) ; (vii) the high-copy-number 2m TRP1 plasmids derived from pRS424 (9) containing the GAL-CYC promoter fused to the cDNAs encoding wild-type PKR (p1545) or the PKR-K296R mutant (p1548) (35a); and (viii) the high-copy-number URA3 GCN3 plasmid p2304 (52) .
The following plasmids were constructed in this study by standard methods (40) . pCP62 contains GCD2 on a 2.6-kb SalI-EagI fragment subcloned from pCP46 (33) into similarly cut YCp50 (32a). The gcd2⌬::hisG plasmid pAV1001 was generated by removing the region between the BglII site 5Ј of the coding region of GCD2 and the EcoRI site near the C terminus in plasmid pCP46 and replacing it with the hisG-URA3-hisG cassette isolated on a BglII-BamHI fragment from pNKY51 (1). The EcoRI and BamHI ends were end filled with Klenow polymerase prior to ligation. The GCD2 LEU2 CEN4 plasmid pAV1002 was constructed by ligating the GCD2 XhoI-to-XbaI fragment isolated from pCP46 with BamHI-cut pSB32 (38) after end filling of both fragments with Klenow polymerase. pAV1003 is a GCD2 CEN4 TRP1 plasmid made by removing the URA3 gene from pCP62 by digestion with EagI and SpeI and ligating the plasmid to the TRP1 gene from pRS304 isolated on an SspI fragment (42) after end filling both fragments with Klenow polymerase. pAV1026 was derived from plasmid pAV1003 in two steps: (i) a region of the tet gene was removed by ClaI digestion and religation, generating pAV1014, and (ii) site-directed mutagenesis was used, as described below, to make a silent mutation in TRP1 that eliminated the BanII site. As a result, the NsiI, NruI, BamHI, BanII, and ClaI sites in GCD2 are unique in pAV1026. p2297 is a high-copy number URA3 GCD2 plasmid constructed by deletion of GCD7 and GCN3 from p1871 (17) by NotI digestion and religation.
Isolation of regulatory mutations in GCD2, GCD7, and GCN3. Three different random mutagenesis procedures were employed to isolate a pool of mutated plasmid DNA from which mutations with the desired phenotype were selected. UV mutagenesis was used for generating GCD2 mutations. While this was FIG. 1. Regions of sequence homology between the GCD2, GCD7, and GCN3 subunits of eIF2B in yeast. The protein-coding sequences of GCD2, GCD7, and GCN3 are depicted schematically from the N terminus to the C terminus (left to right, with the terminal amino acids numbered) as open bars with shaded segments indicating regions of sequence similarity shared by all three proteins. The positions of missense substitutions isolated previously (47) in GCD7 that confer resistance to the growth-inhibitory effects of eIF2(␣P) in vivo are shown above the sequence. In GCD2, the two regions with 60% sequence similarity to GCD7 and GCN3 are interrupted by a region that shows no sequence homology with GCD7 or GCN3.
successful, other, more rapid, random mutagenesis procedures became available, so these were employed instead to generate GCD7 and GCN3 mutations. In addition, it was necessary to isolate dominant mutations in GCN3, as it is nonessential and recessive loss-of-function alleles would also satisfy the selection procedure. This was accomplished by mutagenizing the gene on a high-copynumber plasmid and screening the mutant plasmids for the desired phenotype in a wild-type GCN3 strain. The same strategy was used to isolate dominant GCD2 alleles in an effort to identify mutations that alter GCD2 function without diminishing its capacity for complex formation with other subunits. When the GCD2 alleles thus obtained were analyzed on low-copy-number vectors, their dominance over wild-type GCD2 was diminished. GCD7 was mutagenized on a single-copy plasmid, and plasmid shuffling (3) was used to identify mutant alleles as the only resident copy of GCD7. GCD7 alleles with the strongest phenotypes were found to be semidominant over wild-type GCD7.
GCD2 mutagenesis. Plasmid pCP57 (6), a high-copy-number URA3 plasmid containing the entire GCD2 gene, was subjected to UV mutagenesis in vitro as described previously (35) . Following irradiation, plasmid DNA from ca. 4,000 pooled bacterial transformants was introduced (25) into yeast strain H1613 containing GCD2 and the GCN2 c -516 allele, which confers a Slg Ϫ phenotype (see the introduction). Fast-growing transformants containing plasmid-borne regulatory mutations were identified on the basis of reversion to the Slg Ϫ phenotype when the plasmid was evicted by growth on medium containing 5-fluoroorotic acid (5-FOA) (3). Plasmid DNAs from 63 plasmid-dependent revertants of H1613 were pooled and subcloned into the TRP1 GCD2 plasmid pAV1026 to create four pools of plasmids, each containing a different region of mutagenized GCD2. Each plasmid pool was introduced into the gcd2⌬::hisG GCN2 his1-29 strain GP3173 by plasmid shuffling. Three hundred Ura Ϫ Trp ϩ transformants from each pool were screened for sensitivity to 3-aminotriazole (3AT), an inhibitor of histidine biosynthesis, as described previously (24) . 3AT-sensitive transformants were obtained only from pools constructed from fragments encoding the C-terminal half of GCD2; 80 of these transformants were from plasmids bearing the 560-bp BamHI-BanII fragment, and 171 were from plasmids containing the 757-bp BanII-ClaI fragment. No 3AT-sensitive transformants were isolated from the pools containing the 815-bp NsiI-NruI or 457-bp NruI-BamHI mutagenized fragments encoding the N-terminal half of GCD2. DNA sequence analysis of the subcloned GCD2 fragments in a representative sample of plasmids isolated from the 3AT-sensitive transformants identified seven independent single mutations and one double mutation of adjacent residues in GCD2. The following plasmids contain these eight alleles: pAV1030 (GCD2-E377K) and pAV1031 (GCD2-L381Q), derived from the BamHI-BanII subcloned mutant DNA pool; and pAV1032 (GCD2-F523I), pAV1033 (GCD2-K627T), pAV1034 (GCD2-T630S), pAV1035 (GCD2-A634D), pAV1036 (GCD2-P636T, P637L), and pAV1037 (GCD2-P641F), derived from the BanII-ClaI subcloned mutant pool.
GCD2-I625F was isolated in a separate screen by using error-prone PCR as described previously (7) . The 349-bp GCD2 fragment from position ϩ1554 to ϩ1902 relative to the AUG start codon was amplified from plasmid p2297, digested with NheI and EcoRI, and used to replace the corresponding wild-type fragment in p2297. The resulting pool of plasmids was screened for reversion of the Slg Ϫ phenotype of strain H1613 as described above. The PCR-mutagenized fragment in each plasmid bearing a GCD2 suppressor was sequenced in its entirety, identifying two alleles containing single-amino-acid substitutions: GCD2-I625F (borne on plasmid pWM71) and GCD2-K627T. The latter was also isolated in the screen of UV-mutagenized GCD2 DNA and was not characterized further. pAV1107 (GCD2-I625F) was generated by replacing the GCD2 BamHI-ClaI fragment in pAV1026 with the corresponding fragment from pWM71.
GCD7 mutagenesis. The bacterial mutator strain XL1-Red (Stratagene, La Jolla, Calif.) was used according to the manufacturer's instructions to mutate 0.3 g of the low-copy-number GCD7 LEU2 plasmid p1305 (47) . Plasmid DNA from a pool of 15,000 transformants was introduced into the gcd7⌬ strain H2217 containing wild-type GCD7 on pJB99. The transformants were pooled, and plasmid shuffling was used to evict pJB99. The resulting Ura Ϫ strains (ca. 30,000) were transformed with the URA3 GCN2 c -516 plasmid p1056. From ca. 20,000 of these transformants, 764 fast-growing revertants were selected. Plasmid p1056 was evicted from the revertants on 5-FOA medium, and the Ura Ϫ strains thus obtained were screened for 3AT sensitivity. Fifty-two mutants showed increased sensitivity to 3AT over that of the wild-type GCD7 strain. Of these, 47 yielded plasmids that conferred the 3AT-sensitive phenotype upon reintroduction into strain H2217. Complete nucleotide sequencing of GCD7 in each plasmid identified 11 novel single mutations, which were subcloned into the unmutagenized low-copy-number GCD7 LEU2 plasmid p1558 (47), as follows: pAV1077 (GCD7-F82L), pAV1078 (GCD7-L117S), and pAV1079 (GCD7-S119P) contain subcloned XbaI-SacI fragments; pAV1081 (GCD7-G218R) and pAV1082 (GCD7-R254C) contain subcloned SacI-AvaI fragments; and pAV1083 (GCD7-P291S), pAV1084 (GCD7-V292A), pAV1085 (GCD7-Y305C), pAV1086 (GCD7-P306L), pAV1087 (GCD7-N357I), and pAV1088 (GCD7-S359G) contain subcloned AvaI-EagI fragments. These plasmids were resequenced to confirm the presence of each mutation.
GCN3 mutagenesis. Random mutagenesis of GCN3 was performed by using PCR as previously described (7) . Plasmids containing GCN3 alleles with mutations in the N-terminal portion of the coding region were constructed by amplifying the 843-bp HindIII-ClaI fragment of GCN3 with oligonucleotide primers GN31 (5Ј GAT ACG ACA CAG CAA CAT TGT CGC C) and GN32 (5Ј CCA ACG AAC ACT TTG TCA ACC TAT TCG) and inserting the mutagenized fragments between the corresponding sites of the 2m URA3 GCN3 plasmid p2304. Plasmid DNA was pooled from ca. 20,000 bacterial transformants. Similarly, GCN3 alleles with mutations in the C-terminal portion of the coding region were constructed by using oligonucleotides GN33 (5Ј CGA TAG CGC GGT TGG GCG GTA ATCG) and GN34 (5Ј GGG GGG ATC CAG TTT CAC ATA AAG GAT GCT CTC TTG CGC) as PCR primers to amplify the 466-bp ClaI-BamHI GCN3 fragment that was used to replace the corresponding fragment in p2304. Mutagenized plasmid DNA was prepared from a pool of 150,000 bacterial transformants.
Dominant Gcn Ϫ alleles of GCN3 were selected as described above for the GCD2 regulatory alleles by transforming strain H1613 with the two pools of mutagenized GCN3 plasmids and selecting the fastest-growing revertants. For the N-terminal library, 58 plasmid-dependent revertants were isolated from ca. 10,000 yeast transformants. Sequence analysis of the mutagenized fragments in nine plasmids identified the following five plasmids containing GCN3 alleles with single amino acid substitutions: pWY03 (GCN3-T41A), pWY06 (GCN3-E44V), pWY07 (GCN3-N80D), pWY11 (GCN3-F73L), and pWY12 (GCN3-E44K). From the C-terminal library, 22 revertants were isolated from 54,000 yeast transformants, and sequence analysis of the mutagenized fragments identified four plasmids containing GCN3 alleles with single amino acid changes: pWY101 (GCN3-T291P), pWY103 (GCN3-F240I), pWY106 (GCN3-F240L), and pWY115 (GCN3-S293R).
Site-directed mutagenesis. Site-directed mutagenesis was performed with the Altered Sites II mutagenesis kit (Promega Corp., Madison, Wis.) by using the protocol provided and synthetic oligonucleotides containing the desired nucleotide changes. A derivative of pAlter-1 (Promega Corp.) containing a 3.65-kb HindIII fragment from pAV1014 containing GCD2 and TRP1 (pAV1018) was employed. The BanII site in TRP1 was eliminated in pAV1018 by silent mutagenesis with the oligonucleotide GDP115 (5Ј ACT GGG TTG GAA GGC AAG AAA GTC CCG AAA GCT TGA GTA TTC). Mutagenesis was verified by restriction digestion. The mutagenized HindIII fragment was subcloned back into pAV1014 to generate pAV1026. Specific codons of GCD2 were altered as follows: gcd2-P502S with primer GDP149 (5Ј TCG CAG CAG ACA ATT ACA GAA ATA TTT CTT CTC TTA GCGC), incorporating a novel SspI site; gcd2-S638R with primer GDP150 (5Ј TAA AAT AAC AGG GAC AGA TCT AGG TGG CAA AGC GCC GAAT), incorporating a novel BglII site; and gcd2-S638C with primer GDP152 (5Ј TCT TAA AAT AAC AGG GAC ACT GCA GGG TGG CAA AGC GCC GAA TT), incorporating a novel PstI site. Mutagenesis was verified by restriction digestion and DNA sequence analysis of the GCD2 DNA within the HindIII fragment, after which the appropriate HindIII fragment was subcloned into pAV1026, generating the following plasmids: pAV1102 (gcd2-P502S), pAV1104 (gcd2-S638R), and pAV1105 (gcd2-S638C).
Genetic methods and yeast strain constructions. Standard methods were used for culturing, transformation, and construction of yeast strains (25, 41) . Tests for sensitivity to amino acid analogs have been described previously (24) . Table 1 shows the yeast strains used in this study. All are derived from strain S288C. For the studies comparing plasmid-borne mutations in GCD2, GCD7, or GCN3 (results shown in Fig. 2 to 4, 6, and 7), only the recipient yeast strains (GP3040, GP3140, GP3160, GP3224, GP3514, H1607, H1613, H2218, H2220, and Y117) are listed in Table 1 . Recipient strains bearing chromosomal deletions of GCD2 or GCD7 carried a plasmid-borne wild-type allele of the corresponding gene on a URA3 plasmid (pCP62 for GCD2 and pJB99 for GCD7) that was evicted by growth on 5-FOA medium following introduction of the mutant alleles. Deletion of GCN2 in strains H1515, GP3040, H1645, and GP3153 to generate strains GP3140, GP3224, GP3514, and Y117, respectively, was carried out by using plasmid p1144 as described previously (16) . Disruption of GCN3 with the LEU2 gene in strains H1515 and GP3040 to generate strains GP3153 and GP3160, respectively, was conducted with plasmid Ep146 as described previously (19) . Deletion of GCD2 in strains H1515 and H1645 to generate strains GP3040 and GP3514, respectively, was performed as follows. (i) Plasmid shuffling on 5-FOA medium was used to exchange p919 (SUI2 URA3) with p1097 (SUI2 LEU2) in H1645. (ii) Plasmids containing GCD2, i.e., pAV1002 (GCD2 LEU2) for H1515 and pAV1003 (GCD2 TRP1) for H1645, were introduced, and the chromosomal copy of GCD2 was deleted by transforming with plasmid pAV1001, bearing the gcd2⌬::hisG-URA3-hisG allele, after digestion with XbaI and SalI. The hisG-URA3-hisG cassette was evicted by growth on 5-FOA medium, leaving the gcd2⌬::hisG allele in the chromosome (1). (iii) Southern hybridization analysis (43) was carried out to confirm the replacement of chromosomal GCD2 with the gcd2⌬::hisG allele by digesting chromosomal DNA with XbaI and HpaI and using the 1,470-bp StuI-XbaI GCD2-hisG fragment from pAV1001 as the hybridization probe (data not shown). Strain GP3173 is a meiotic segregant of a cross between GP3040 and H1486.
Isoelectric-focusing gel electrophoresis and detection of eIF2␣ phosphorylation. One-dimensional isoelectric-focusing polyacrylamide gel electrophoresis was carried out on total cellular proteins, followed by immunoblot analysis with antibodies against eIF2␣ and detection of immune complexes with enhanced chemiluminescence (Amersham) exactly as described previously (16) except for the addition of 2-aminopurine to the cell-breaking buffer (36) . The percentage of eIF2␣ that was phosphorylated at Ser-51 was determined by densitometry of autoradiograms.
Multiple sequence alignment. The following sequences were obtained from the GenBank sequence database (with accession numbers shown in parentheses): GCN3 (P14741), GCD2 (P12754), GCD7 (P32502), Caenorhabditis elegans eIF2B␣ (P34604), rat eIF2B␣ (U05821), and rat eIF2B␦ (Z48225). The human eIF2B␤ sequence (L4039) obtained from a full-length cDNA clone was identified in a BLAST search (2) and modified after alignment with 16 short overlapping sequences covering the entire sequence from the expressed sequence tag database (dbEST). Modifications included resolution of ambiguous nucleotides and minor reading frame adjustments to generate a full-length sequence that was nearly identical to the recently published rabbit sequence (13) . The multiple sequence alignment shown in Coimmunoprecipitation of eIF2B subunits. Ribosomal salt wash (RSW) fractions were prepared from 1 liter of yeast cells grown in yeast extract-peptonedextrose medium to an optical density at 600 nm of approximately 6, as described previously (17) . Coimmunoprecipitation of eIF2B subunits with anti-GCD6 antiserum was performed as described previously (6, 17) except that 4 l of GCD6-specific antiserum or 10 l of preimmune antiserum was used to immunoprecipitate eIF2B from 400 g of RSW.
RESULTS
Regulatory mutations in the GCD2 subunit of eIF2B cluster within regions of sequence similarity between GCD2, GCD7, and GCN3. Previously, we hypothesized that regions of GCD2 and GCD7 that have sequence homology with GCN3 would be important for negative regulation of eIF2B by eIF2(␣P) (22) . The fact that only the C-terminal half of GCD2 has sequence similarity with GCD7 and GCN3 allowed us to test this idea. We reasoned that it should be possible to isolate single amino acid substitutions in GCD2 which render eIF2B insensitive to eIF(2␣P) and that many of these mutations would be restricted to regions of sequence similarity between GCD2, GCD7, and GCN3. To isolate GCD2 regulatory mutations, we performed in vitro mutagenesis of the entire cloned gene and screened mutagenized plasmids for suppression of the slow-growth phenotype (Slg Ϫ ) due to eIF2␣ hyperphosphorylation by an activated GCN2 kinase. High-copy-number GCD2 plasmid DNA was mutagenized by UV irradiation and introduced into a GCD2 GCN2 c -516 yeast strain (H1613), after which dominant GCD2 mutations were selected as fast-growing (Slg ϩ ) revertants (see Materials and Methods). By this approach, we identified eight independent suppressor alleles, seven containing single missense mutations and one with a pair of mutations at adjacent residues in the GCD2 coding sequence (P636T and P637L) ( Fig. 2A) . One additional allele was generated by PCR amplification of GCD2 and identified by the same screening procedure. Interestingly, all of the substitutions were located in regions of sequence similarity between GCD2, GCD7, and GCN3 in the C-terminal half of GCD2. In addition, the mutations appeared to cluster at three sites in this portion of GCD2, with the majority mapping in the most highly conserved segment near the C terminus. The suppressor phenotype of these alleles was evident in the presence of chromosomally encoded GCD2, suggesting that the mutant proteins compete with wild-type GCD2 for incorporation into eIF2B and decrease the sensitivity of the mutant complex to eIF2(␣P).
To characterize the effects of these suppressor mutations when the mutant proteins were expressed as the only GCD2 present in the cell, we subcloned all nine mutant alleles onto single-copy plasmids and introduced them by plasmid shuffling (3) into yeast strains with the chromosomal GCD2 gene deleted. In these strains all of the suppressor alleles fully reverted the Slg Ϫ phenotype of GCN2 c -516, the allele which they were selected to suppress (Fig. 2B) . We also examined whether the GCD2 alleles would interfere with the ability of wild-type GCN2 to stimulate translation of GCN4 mRNA in response to amino acid starvation. As described in the introduction, the level of GCN4 translation is very sensitive to reductions in the activity of eIF2B. A simple and well-characterized assay for GCN4 translation is to monitor growth of yeast in the presence of 3AT, an inhibitor of the HIS3-encoded step in histidine biosynthesis. Histidine deprivation causes an accumulation of uncharged tRNA His , which stimulates the ability of GCN2 to phosphorylate eIF2 and thereby inhibit eIF2B. The resulting reduction in ternary complex levels causes increased GCN4 synthesis and HIS3 transcription. Thus, regulatory mutations in eIF2B that prevent increased GCN4 translation in response to histidine starvation decrease the ability of these cells to grow in the presence of 3AT. All nine GCD2 suppressors conferred increased sensitivity to 3AT in strains bearing wild-type GCN2. Three of the GCD2 suppressors (GCD2-E377K, -L381Q, and -K627T) showed the same 3AT sensitivity conferred by deletion of GCN2, suggesting that little or no increase in GCN4 expression occurred in response to eIF2 phosphorylation in these mutants (Gcn Ϫ phenotype). The other six GCD2 mutations appeared to reduce, but not abolish, derepression of GCN4 and HIS3 expression in response to eIF2(␣P), as they showed only decreased resistance to 3AT (Fig. 2C) .
Resistance to 3AT in strains with GCN2 deleted is a very sensitive indicator of reduced catalytic function of eIF2B and has been used to isolate many reduced-function mutations in eIF2B subunits (10, 20) . To assess whether any of the regulatory mutants isolated here also showed a catalytic defect, the growth of gcn2⌬ strains bearing the GCD2 suppressor alleles on medium containing 3AT was examined. None of the GCD2 suppressors described here (or the GCD7 and GCN3 suppressors described below) led to detectable growth on 3AT medium in the gcn2⌬ background (data not shown). In addition, none of the suppressors reduced the rate of colony formation in the GCN2 strains under nonstarvation conditions (Fig. 2C , SD medium). Together these results indicate that the suppressor mutations do not impair the catalytic activity of eIF2B.
We also tested the GCD2 suppressors in a strain bearing GCN2 c -513, encoding a hyperactivated kinase that phosphorylates eIF2 in vivo at higher levels than are produced by the GCN2 c -516 allele used in the genetic selection (35) . The three GCD2 alleles with the strongest Gcn Ϫ phenotype in the GCN2 strain were also completely sensitive to 3AT and fully suppressed the Slg Ϫ phenotype on SD medium in the GCN2 c -513 background. Similarly, the GCD2 alleles with a weaker Gcn c kinase. Transformants of gcd2⌬ gcn2⌬ strain GP3224 bearing the wild-type or the indicated mutant allele of GCD2 and the indicated allele of GCN2 were streaked for single colonies on minimal medium (SD) supplemented with leucine, isoleucine, and valine and grown for 2.5 days at 30ЊC. (C) Summary of genetic analysis. The growth of transformants of gcd2⌬ gcn2⌬ strain GP3224 bearing one plasmid containing the indicated GCD2 allele (see Materials and Methods for plasmid designations) and a second plasmid containing either wild-type GCN2 (p722), the GCN2 c -513 allele (p1052), or PKR cDNA under the control of a hybrid GAL10-CYC1 promoter (p1420) was examined as follows: (i) by streaking for single colonies on SD minimal medium, with the maximum growth rate designated 5ϩ; (ii) by replica plating on SD medium supplemented with 3AT to induce histidine starvation, with the maximum growth rate designated 3ϩ; and (iii) by streaking for single colonies on minimal medium containing galactose in place of glucose as a carbon source (SGAL), with the maximum growth rate designated 5ϩ. In each case, no detectable growth was scored as 0, and 1ϩ Ͼ ϩ/Ϫ Ͼ Ϫ/ϩ Ͼ 0. Mutations that rendered strains completely or largely insensitive to the effects of eIF2 phosphorylation are shaded.
phenotype only partially suppressed the Slg Ϫ phenotype and were resistant to 3AT in the GCN2 c -513 strain (Fig. 2C) . Overexpression of the mammalian eIF2␣ kinase PKR in place of GCN2 is lethal in yeast due to extreme levels of eIF2␣ phosphorylation on Ser-51 (8, 15) . Suppression of this lethality was used as another means of ranking the GCD2 mutations. Again, the three mutants that exhibited the strongest Gcn Ϫ phenotypes in the strains containing the GCN2 c alleles also were the most effective in suppressing the lethal effects of PKR overexpression. Indeed, the GCD2-L381Q and -K627T alleles completely overcame the toxicity of PKR expression, as they grew indistinguishably from an isogenic strain with the alanine-51 substitution in eIF2␣ (Fig. 2C) . These last results suggested that the L381Q and K627T substitutions in GCD2 make eIF2B completely insensitive to eIF2␣ phosphorylation. The E377K substitution is slightly less effective, and the other six mutations are considerably less effective than are L381Q and K627T in overcoming the inhibitory effects of eIF2(␣P) on eIF2B recycling activity.
Regulatory mutations in GCD7 and GCN3 alter residues in segments homologous to GCD2. The mutational analysis described above identified three regions in the C-terminal half of GCD2 with an important role in negative regulation of eIF2B by eIF2(␣P). We considered the possibility that homologous segments in GCD7 and GCN3 would also be involved in the regulatory functions of eIF2B. To test this hypothesis, we isolated point mutations in GCN3 and additional mutations in GCD7 as suppressors of GCN2 c -516, to compare the locations of a large number of regulatory substitutions obtained in the three different proteins.
A low-copy-number GCD7 plasmid was mutagenized in a bacterial mutator strain and introduced into a gcd7⌬ GCN2 c -516 strain by plasmid shuffling. The resulting strains were screened for reversion of the Slg Ϫ phenotype of the GCN2 c -516 allele. We obtained 11 novel suppressor alleles and characterized them in parallel with the GCD7 regulatory alleles described previously (47) by the genetic tests used as described above to rank the GCD2 suppressors (Fig. 3) . One of the new suppressors, GCD7-S119P, resembled the GCD2-L381Q and GCD2-K627T alleles, conferring complete insensitivity to eIF2 phosphorylation. Previously, this extreme phenotype was achieved for GCD7 only by combining two mutations, GCD7-1118T, D178Y (Fig. 3) (47) . All of the GCD7 regulatory mutations alter amino acids within regions of sequence similarity in GCD7, GCD2, and GCN3, with none occurring in the unconserved N-terminal 65 residues of GCD7 (Fig. 3A) . In addition, eight of the complete set of 15 GCD7 suppressors (substitutions P291S, V292A, Y305C, P306I, K329E, I348V, N357I, and S359G) mapped within, or just upstream of, the highly conserved C-terminal domain (Fig. 3A) , verifying the Methods for plasmid designations) on a high-copy-number URA3 plasmid was introduced into strains H1613 (GCN2 c -516) and H1607 (GCN2 c -513) or introduced together with a second plasmid expressing the PKR cDNA from a hybrid GAL10-CYC1 promoter (p1545) into strains GP3140 (gcn2⌬) and Y117 (gcn2⌬ gcn3::LEU2). The growth of these transformants was examined as described in the legend to Fig. 2C . All of the GCN3 mutations rendered the strains completely insensitive to the effects of eIF2 phosphorylation.
importance of this region in the regulatory functions of both GCD7 and GCD2. Five mutations in GCD7 (F82L, L117S, I118T, S119P, and D178Y) were located in the N-terminal region of similarity with GCD2 (Fig. 3A) , where the E377K and L381Q mutations in GCD2 mapped, indicating the importance of this region also for the regulatory functions of both subunits.
To confirm that the phenotypes of the mutations that we isolated in GCD2 and GCD7 were not caused by variations in the levels of the subunits of eIF2B, we used immunoblot analysis to analyze the steady-state levels of GCD2, GCD6, GCD7, and GCN3 in strains containing each of the suppressor alleles. We observed no significant variations from the wild-type levels of these proteins in any mutant (data not shown).
Error-prone PCR mutagenesis of GCN3 and screening of mutagenized plasmids for dominant suppression of the Slg Ϫ phenotype of a GCN3 GCN2 c -516 strain was used to isolate dominant suppressors in GCN3. In this case, only the fastestgrowing revertants were selected for analysis. The resulting nine alleles contained single-codon substitutions in GCN3 that displayed a pattern of clustering similar to that seen for the GCD2 and GCD7 mutations (Fig. 4A) . These alleles were characterized by the genetic tests used to rank GCD2 and GCD7 suppressors (Fig. 4) . All nine GCN3 suppressors resembled GCD2-L381Q, GCD2-K627T, and GCD7-S119P in completely overcoming the growth defects associated with eIF2␣ phosphorylation. This was surprising because even deletion of GCN3 does not completely overcome the toxicity of PKR overexpression in yeast cells. Thus, single amino acid changes in GCN3 can make eIF2B less sensitive to eIF2(␣P) than does removing GCN3 from the complex.
Regulatory mutations cluster within two segments in each subunit. The relative positions of the suppressor mutations that we isolated in GCD2, GCD7, and GCN3 are summarized in Fig. 5A . With the exception of three substitutions in GCD7 (F82L, G218R, and R254C), all other mutations map in either of two segments of GCD2, GCD7, and GCN3. A ca. 70-residue segment located at the highly conserved C terminus of each protein encompasses seven of the nine mutations in GCD2 and roughly half of the mutations in GCD7 and GCN3 (Fig. 5A ). This segment in GCD2 is interrupted by a 51-amino-acid region of nonhomology. The rest of the mutations fall into a second ca. 70-residue segment located near the N-terminal boundary of the region of shared homology in each protein (Fig. 5A ). These observations suggest that homologous structural elements in GCD2, GCD7, and GCN3 mediate the regulatory functions of these proteins and imply that the regulatory functions of GCD2, GCD7, and GCN3 are closely related.
To investigate whether any of the suppressor mutations alter equivalent positions in the homologous segments of GCD2, GCD7, and GCN3, we constructed a multiple sequence alignment of the yeast eIF2B subunits and their homologs in C. elegans and mammalian species. Figure 5B and C display two sections from this alignment encompassing the N-terminal and C-terminal clusters of regulatory mutations, respectively. We found that suppressors mapping in the C-terminal clusters (Fig. 5C ) had substituted residues at equivalent positions in GCD2 and GCD7 (GCD7-I348V and GCD2-K627T), in GCD7 and GCN3 (GCD7-S359G and GCN3-S293R), or even in all three subunits (GCN3-T291P, GCD7-N357I, and GCD2-P636T) (Fig. 5C ). In addition, GCD2-F523I and the Y305C and P306L mutations in GCD7 are only several residues away from The protein-coding sequences of GCD2, GCN3, and GCD7 are depicted as in Fig. 1 with the addition of all of the regulatory mutations described in Fig. 2, 3 , and 4. Horizontal bars indicate the ca. 70-amino-acid intervals containing the Nand C-terminal clusters of regulatory mutations for each protein. The GCD2 C-terminal cluster is interrupted by a 51-residue stretch with no homology to GCN3 or GCD7. (B and C) Multiple sequence alignment of eIF2B proteins. Three eIF2B␣ sequences (rat, C. elegans, and yeast) were aligned with two eIF2B␤ sequences (human and yeast) and two eIF2B␦ sequences (rat and yeast). Two parts of the alignment, containing the N-terminal (B) and C-terminal (C) clusters of mutations, are shown. Residues mutated in the yeast subunits are indicated, with the substituting amino acid in the mutant shown directly below. In addition, pound symbols (#) directly above each row of the alignment highlight the clustering of these mutated residues. Gaps introduced into the alignment are shown with dots, and nonsense codons are shown with asterisks. Boxes indicate residues identical in at least five of the seven sequences. Conservative substitutions in at least five of seven residues are shaded.
the F240I and F240L changes in GCN3. These results indicate that certain positions in the extreme C-terminal domains of all three subunits carry out critical regulatory functions, providing further evidence that these regions are both structurally and functionally related.
Many critical regulatory residues are located at unique positions within the homologous segments. Although several of the regulatory substitutions in the C-terminal clusters altered equivalent positions in the three proteins (Fig. 5C) , this was not true of others in this segment, nor did it apply to any of the suppressor mutations in the N-terminal clusters. Figure 5B shows that the mutations in the latter region form four independent clusters separated from each other by 12 to 26 residues. Thus, all of the critical residues identified in the Nterminal conserved segments are at unique positions in each subunit. It was conceivable that our mutagenesis experiments did not saturate the regulatory sites in these proteins and that equivalent positions are actually critical for regulation more frequently than our results indicate. In an effort to rule out this possibility, we pursued the fact that suppressors were obtained which alter identical residues at the same positions in the C-terminal segment of GCD7 at Ser-359 and in GCN3 at Ser-293, whereas none were isolated at the corresponding position in GCD2 (Ser-638). If this occurred because the mutagenesis of GCD2 was not saturating, then alteration of Ser-638 in GCD2 should have a suppressor phenotype. To test this prediction, we used site-directed mutagenesis to replace Ser-638 in GCD2 either with Arg, the nonconservative replacement at the homologous position in GCN3-S293R (Fig. 5C) , or with Cys. In parallel, we altered Pro-502 in GCD2 to Ser because the homologous Pro residue had been altered in GCD7-P291S and also because this is the only residue altered in one of our suppressors that is invariant among GCD2, GCD7, GCN3, and their homologs in higher eukaryotes (Fig.  5C ). As described next, neither GCD2 mutation had the suppressor phenotype. VOL. 17, 1997 REGULATORY MUTATIONS IN eIF2B 1305
The gcd2-S638R mutation led to a Slg Ϫ phenotype under nonstarvation conditions in an otherwise wild-type strain and conferred resistance to 3AT in a gcn2⌬ background (Fig. 6A) . These phenotypes are characteristic of recessive gcd mutations, which are thought to reduce the catalytic activity of eIF2B.
gcd2-S638R also conferred increased resistance to the amino acid analogs 5-fluorotryptophan and 1,2,4-triazolealanine, additional phenotypes of gcd mutations resulting from constitutive derepression of GCN4 and its target enzymes in the tryptophan and histidine biosynthetic pathways. Interestingly, both the Gcd Ϫ and Slg Ϫ phenotypes of the gcd2-S638R allele were expressed only when GCN3 was present in the cell. Thus, deletion of GCN3 in the gcd2-S638R strain conferred growth rates on SD and SD-3AT medium identical to those observed in the isogenic GCD2 gcn3⌬ strain (Fig. 6A) . Nearly identical results were obtained when Ser-638 in GCD2 was changed to cysteine (data not shown). Interestingly, GCN3 appears to be maintained in the eIF2B complex even though its inclusion facilitates the deleterious effects of the Ser-638 substitutions in GCD2 on the cellular growth rate.
The gcd2-P502S allele also did not exhibit the regulatory phenotype observed for the homologous substitution in GCD7 (P291S). Our initial genetic analysis revealed no phenotypic differences between this mutant allele and wild-type GCD2 (Fig. 6A) . Upon further analysis, however, we observed phenotypes consistent with the idea that the P502S substitution in GCD2 makes eIF2B hypersensitive, rather than insensitive, to eIF2 phosphorylation. gcd2-P502S had no detectable effect on growth under nonstarvation conditions in wild-type GCN2 cells, but it exacerbated the Slg Ϫ phenotype of the GCN2 c -516 and GCN2 c -513 alleles under the same conditions (Fig. 6B) . Although gcd2-P502S had no effect on 3AT sensitivity in a gcn2⌬ strain, it increased 3AT resistance in the gcn2-507 background. The gcn2-507 allele encodes a protein kinase that phosphorylates eIF2␣ at reduced levels under histidine starvation conditions, causing reduced growth on 3AT medium (49) . The partial restoration of growth on 3AT medium in the gcn2-507 strain plus the exacerbation of the slow growth in the GCN2 c strains can be explained if this mutant eIF2B is inhibited more effectively than wild-type eIF2B by phosphorylated eIF2. As a further test of this idea, we examined genetic interactions between gcd2-P502S and mutations in eIF2␣ at the phosphorylation site, serine-51. As expected, the gcd2-P502S allele had no phenotype in the strain containing wild-type or the Ala-51 mutant of eIF2␣. In contrast, combining gcd2-P502S with the Asp-51 form of eIF2␣ significantly reduced growth on SD medium (Fig. 6C [Ala-51 not shown] ). We showed previously that eIF2␣-S51D mimics phosphorylation of Ser-51 in vivo by eliciting partial derepression of GCN4 translation (16) . Thus, the synergistic growth defect seen when eIF2␣-S51D is combined with the gcd2-P502S product is also consistent with the idea that eIF2B containing P502S in GCD2 is hypersensitive to phosphorylated eIF2.
In conclusion, none of the GCD2 alleles constructed by site-directed mutagenesis exhibited the suppressor phenotype. Therefore, although the suppressor mutations cluster in homologous segments in GCD2, GCD7, and GCN3, many positions in these segments that are critically required for regulation differ among the three proteins.
The regulatory mutations do not exclude GCN3 from eIF2B. Deletion of GCN3 makes the resulting four-subunit eIF2B complex less sensitive to eIF2 phosphorylation ( Fig. 4B and  6A) . It was possible, therefore, that the regulatory mutations we isolated in GCD2, GCD7, and GCN3 exert their effects primarily by excluding GCN3 from eIF2B. Several genetic observations suggested that this was not true. For the GCN3 suppressors, all of the mutations are dominant over the wildtype allele, implying that the mutant proteins are replacing wild-type GCN3 in the eIF2B complex. Second, high-level expression of PKR in yeast is lethal, and deletion of GCN3 only partially overcomes this lethality, resulting in a Slg Ϫ phenotype FIG. 6 . Site-directed mutagenesis reveals different functions for equivalent positions in GCD2, GCD7, and GCN3. (A) Plasmids bearing wild-type GCD2 (pAV1026), gcd2-S638R (pAV1104), or gcd2-P502S (pAV1102) were introduced by plasmid shuffling into strains with GCD2 alone deleted (gcd2⌬; strain GP3040) or also lacking GCN2 (gcd2⌬ gcn2⌬; strain GP3224) or GCN3 (gcd2⌬ gcn3⌬; strain GP3160). The resulting transformants were analyzed for growth defects by streaking for single colonies on SD medium containing the appropriate supplements and by replica plating to the same medium supplemented with 3AT, as described in the legend to Fig. 2C . Replica plating to SD medium supplemented with 5-fluorotryptophan and 1,2,4-triazoleanaline was also measured, with the maximum growth rate scored as 3ϩ. Growth differing from that of the wild-type GCD2 strain is shown shaded. n.d., not determined. (B) Strain GP3224 (gcd2⌬ gcn2⌬) bearing GCD2 or gcd2-P502S was transformed with one of the following plasmid-borne alleles of GCN2 or with empty vector (p713): wild-type GCN2 (p722), GCN2 c -516 (p1056), GCN2 c -513 (p1052), or GCN2-507 (p561). Growth was assessed as described in the legend to Fig. 2C , and key results are shaded. (C) Derivatives of GP3514 (gcd2⌬ sui2⌬ gcn2⌬) containing GCD2, gcd2-P502S, and plasmid-borne SUI2 alleles encoding wild-type eIF2␣ (p1097) or eIF2␣-S51D (p1101) were streaked for single colonies on minimal medium supplemented with uracil (SD) and grown for 2.5 days at 30ЊC.
( Fig. 4B and 7A) . In contrast, all of the GCN3 suppressors (Fig. 4B ) and several mutations in GCD2 (E377K, L381Q, and K627T) (Fig. 7A and B) and GCD7 (S119P, P291S, and I348V) (Fig. 7C) completely overcame the toxicity of PKR expression. These results provide strong evidence that all of the products of the GCN3 suppressors are stable components of the eIF2B complex in vivo. Moreover, elimination of GCN3 from eIF2B, even if it occurs, cannot be the sole reason why eIF2B is resistant to eIF2(␣P) in strains containing the most potent GCD2 and GCD7 suppressors.
A third argument that the GCD2 and GCD7 suppressors do not simply cause GCN3 to dissociate from eIF2B is that the phenotype of many suppressor alleles is actually dependent on the presence of GCN3. We made this observation by examining the ability of each GCD2 and GCD7 suppressor to overcome the toxicity of PKR overexpression in a pair of isogenic GCN3 and gcn3⌬ strains. Based on the results shown in Fig. 7B and C, the suppressors were placed in three different classes. Class I contains mutations that overcome the toxicity of eIF2(␣P) more effectively in the GCN3 strain than in the gcn3⌬ mutant. This behavior was observed for the three most efficient GCD2 suppressors (GCD2-E377K, -L381Q, and -K627T) and for the two most effective GCD7 suppressors (GCD7-S119P and -I118T,D178Y). For example, the GCD2-K627T and GCD7-S119P alleles fully suppressed the toxicity of PKR overexpression in the GCN3 strain but appeared to have no phenotype in the isogenic gcn3⌬ strain, with the double mutants exhibiting the same Slg Ϫ phenotype seen in the GCD2 gcn3⌬ and GCD7 gcn3⌬ strains overexpressing PKR (Fig. 7B  and C) . The other two mutations placed in this class show more extreme changes in the gcn3⌬ strain. GCD7-I348V, and to a lesser extent GCD7-V292A, grow slowly on minimal SD medium when combined with gcn3⌬ (not shown), and they also grow on 3AT-containing medium (Fig. 7C) . This implies that when these mutations in GCD7 and gcn3⌬ are combined, the eIF2B complexes formed have reduced catalytic activity. Because the mutations in class I suppress the toxic effects of eIF2(␣P) in the presence of GCN3 but not in its absence, it is highly unlikely that they exert their effects by excluding GCN3 from eIF2B.
All of the suppressor mutations in class II only partially suppressed the lethality of PKR in the GCN3 background, and suppression by these mutations was enhanced by deletion of GCN3. Thus, the level of suppression observed for the class II mutations in the gcn3⌬ background was greater than that conferred by gcn3⌬ alone (Fig. 7B and C) . The additive effects of combining these GCD2 or GCD7 suppressors with gcn3⌬ implies that the class II substitutions act independently of GCN3 rather than by excluding GCN3 from the complex.
The class III mutations are not dependent on GCN3 for suppression and do not have an additive effect when combined with gcn3⌬. With the exception of GCD7-P291S, the mutations in this class suppress PKR toxicity in the GCN3 strain less than the gcn3⌬ mutation does, and they produce no additional suppression when combined with gcn3⌬. The fact that these mutations are phenotypically silent in a gcn3⌬ strain could indicate that they act primarily by reducing the amount of GCN3 stably associated with the eIF2B complex. However, because GCD7-P291S suppresses PKR toxicity more effectively than does gcn3⌬, exclusion of GCN3 from eIF2B cannot be the sole mechanism of suppression for this mutation; indeed, biochemical evidence (described below) shows that for this and other mutants, GCN3 remains stably associated with eIF2B.
With the exception of suppressors in class III, the genetic interactions just described strongly suggest that these mutations do not exclude GCN3 from eIF2B as the primary means of decreasing sensitivity to eIF2(␣P). To obtain physical evidence supporting this conclusion, coimmunoprecipitation experiments were performed to evaluate the relative amounts of GCN3 that are complexed with the GCD6 subunit of eIF2B in the suppressor mutants. We have shown previously that antibodies against GCD6 specifically and quantitatively coimmunoprecipitate all five subunits of eIF2B from cell extracts (6) . For our studies, we selected three GCD2 and three GCD7 mutants, representing each class of suppressors identified by the genetic analysis described above (Fig. 7) . From the data shown in Fig. 8 , it can be seen that GCN3 was equally coimmunoprecipitated with GCD6 from high-salt extracts of pelleted ribosomes prepared from the mutant and wild-type strains. These results show that the GCD2 and GCD7 suppres- FIG. 7 . Genetic evidence that mutations in GCD2 and GCD7 do not exclude GCN3 from eIF2B. (A) Suppression of the toxicity of overexpressing PKR in yeast by mutations affecting eIF2B subunits. Transformants of isogenic strains bearing the PKR cDNA with the GAL10-CYC promoter, selected from those shown in Fig. 2 and 4 , were streaked for single colonies on minimal galactose medium (SGAL) and grown for 7 days at 30ЊC in parallel with the following control strains: (i) a transformant of GP3224 (gcd2⌬ gcn2⌬) containing the plasmid-borne cDNA encoding the catalytically defective mutant PKR-K296R (p1421) and (ii) strain H1645 (sui2⌬) containing plasmids encoding eIF2␣-S51A (p1098) and wild-type PKR (p1420). (B) Effects of deleting GCN3 on phenotypes of GCD2 regulatory mutants. Strains GP3224 (gcd2⌬ GCN3), GP3160 (gcd2⌬ gcn3⌬), and GP3160 containing p1420 encoding PKR were transformed with plasmids bearing the indicated GCD2 alleles. Growth of the resulting transformants was assessed as described in the legend to Fig. 2C . The three categories of mutations (classes I, II, and III) are described in the text. (C) Effects of deleting GCN3 on phenotypes of GCD7 mutants. Phenotypic analysis identical to that shown in panel B was performed for GCD7 mutants by using transformants of strains H2218 (gcd7⌬ GCN3) and H2220 (gcd7⌬ gcn3⌬). n.d., not determined.
sor mutations in these six strains do not act by excluding GCN3 from eIF2B and confirm our interpretation of the genetic data in Fig. 7 . We conclude that GCD2, GCD7, and GCN3 each play a direct role in the regulation of eIF2B activity by phosphorylated eIF2 and that a single missense change in any one of these three subunits is sufficient to disrupt the regulatory mechanism.
eIF2␣ is highly phosphorylated in eIF2B mutants expressing PKR. It was conceivable that the suppressor mutations overcome the toxicity of GCN2 c alleles and PKR expression by decreasing the level of eIF2␣ phosphorylation. Therefore, we examined eIF2␣ phosphorylation in GCD2 mutant strains by using isoelectric-focusing gel electrophoresis of whole-cell extracts followed by immunoblot analysis with eIF2␣-specific antiserum. When PKR expression was induced in the wild-type GCD2 strain, a portion of eIF2␣ became phosphorylated in a manner that was completely dependent on PKR and Ser-51 in eIF2␣, being abolished by the K296R substitution in PKR or the Ala-51 substitution in eIF2␣ (Fig. 9, lanes 1, 2, and 11) . We showed previously that the L84F substitution in eIF2␣, which renders eIF2(␣P) impotent as an inhibitor of eIF2B, leads to a higher level of eIF2(␣P) in vivo than occurs in isogenic wildtype eIF2␣ cells (Fig. 9, lanes 1 and 12) (46) . This increase in the level of eIF2(␣P) appears to result from increased expression of PKR under conditions where eIF2␣ phosphorylation does not inhibit translation initiation (36) . We observed the same phenomenon for the GCD2 suppressors; moreover, the percentage of eIF2␣ phosphorylation correlated with the degree of suppression of PKR toxicity by the different mutations (Fig. 9, lanes 3 to 10, and Fig. 2 ). These results, together with similar findings for GCD7 suppressors (47) and for gcn3⌬ (15) , confirm that the regulatory mutations do not overcome the toxicity of PKR by reducing phosphorylation of eIF2␣. Moreover, the fact that ca. 80% of the eIF2␣ is phosphorylated in the GCD2-L381Q and GCD2-K627T suppressor strains suggests that these two mutations, and perhaps others, allow FIG. 8 . Coimmunoprecipitation of GCN3 with GCD6 from strains bearing regulatory mutations in GCD2 or GCD7. (A) RSW fractions were prepared from strain GP3040 (gcd2⌬) containing the following GCD2 alleles: wild-type GCD2 (pAV1026), GCD2-L381Q (pAV1031), GCD2-T630S (pAV1034), and GCD2-A634D (pAV1035). eIF2B complexes were immunoprecipitated from these fractions by using polyclonal antiserum raised against the GCD6 subunit of eIF2B. Eighty-three micrograms of RSW (Input), the coimmunoprecipitation pellets obtained from 166 g of RSW, and the supernatants remaining after immunoprecipitation from 83 g of RSW were separated by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis, blotted to nitrocellulose, and probed with rabbit polyclonal sera against eIF2B subunits as described previously (6, 10, 11) . Bound antiserum was detected by using horseradish peroxidase-linked protein A and enhanced chemiluminescence. Staining of nitrocellulose membranes with Ponceau S (Sigma) showed that the coimmunoprecipitations were specific, as all visible input proteins were retained in the supernatant fractions. For simplicity, only the coimmunoprecipitation of GCN3 with GCD6 is shown; however, GCD1, GCD2, and GCD7 were found to be distributed between pellet and supernatant fractions similarly to GCN3 and GCD6. Whole-cell extracts from yeast strains with eIF2B subunits on low-or high-copy-number plasmids (prepared as described in reference 17) were analyzed in parallel to identify unambiguously each immunoreactive species. (B) Same as for panel A except that transformants of strain H2217 (gcd7⌬) bearing the following plasmids containing the indicated GCD7 alleles were analyzed: GCD7-S119P (pAV1079), GCD7-P291S (pAV1083), and GCD7-S359G (pAV1088). Identical control immunoprecipitation reactions with 10 l of GCD6 preimmune serum failed to precipitate any eIF2B proteins (data not shown) (6). eIF2B to catalyze nucleotide exchange on phosphorylated eIF2.
DISCUSSION
Homologous segments in GCD2, GCD7, and GCN3 function in the regulation of eIF2B by phosphorylated eIF2. eIF2B is unique among guanine nucleotide exchange factors in being regulated by phosphorylation of its substrate, eIF2. Experiments with purified mammalian factors have shown that eIF2(␣P) ⅐ GDP acts as an inhibitor of eIF2B, preventing the recycling of nonphosphorylated eIF2 ⅐ GDP to eIF2 ⅐ GTP. We previously proposed that regions of sequence homology shared by three of the eIF2B subunits, GCN3, GCD7, and the C-terminal half of GCD2, all function in this regulatory step (22) . This idea was based on the fact that deletion of GCN3 appears to make eIF2B less sensitive to eIF2(␣P) and on the isolation of several GCD7 point mutations with the same phenotype. The results presented in this report provide strong support for this hypothesis and identify particular segments in the homologous regions of GCD2, GCD7, and GCN3 that are critically required for their regulatory functions.
We have isolated 29 novel mutations in GCD2, GCD7, and GCN3 that reduce or abolish the response to eIF2(␣P) without causing an apparent defect in eIF2B catalytic activity. These regulatory mutations are not distributed randomly throughout each subunit. First, all of the GCD2 suppressors map in the C-terminal half of the protein, which is homologous to GCD7 and GCN3. Second, almost all of the regulatory mutations are clustered in two segments of ca. 70 amino acids in each subunit, located at the amino and carboxyl ends of the region of sequence similarity (Fig. 5A) . Several substitutions in the Cterminal clusters of mutations alter residues at equivalent positions in two of the three subunits or even in all three proteins (Fig. 5C ). The fact that homologous segments, and even identical amino acid positions, in GCD2, GCD7, and GCN3 are critically required for inhibition of eIF2B by eIF2(␣P) implies that structurally similar elements in these proteins carry out related functions in the regulatory mechanism. As described below, we propose that these three subunits form a single regulatory domain in eIF2B, which makes multiple contacts with eIF2␣ around the site of phosphorylation at Ser-51, allowing eIF2B to sense and respond to eIF2␣ phosphorylation.
GCD2, GCD7
, and GCN3 make independent contributions to the regulation of eIF2B by eIF2(␣P) as components of a single regulatory domain. The fact that single mutations were obtained in GCD2, GCD7, and GCN3, each of which abolishes negative regulation of eIF2B by eIF2(␣P), suggests that all three proteins play critical roles in the regulatory mechanism. However, it could be imagined instead that the mutations in GCD2 and GCD7 impair regulation indirectly by affecting the function of GCN3. One way that this might occur is for mutations in GCD2 or GCD7 to cause dissociation of GCN3 from the eIF2B complex. This possibility was eliminated for most of the regulatory mutations we isolated by a combination of genetic and biochemical experiments. The coimmunoprecipitation data in Fig. 8 showed that GCN3 was present at normal levels in the eIF2B complexes found in a number of strains containing different GCD2 and GCD7 suppressors analyzed by this technique. In addition, genetic experiments showed that the regulatory effects of several GCD2 and GCD7 mutations (designated class I alleles) are greatly dependent on the presence of GCN3 (Fig. 7) , indicating that GCN3 resides in these mutant eIF2B complexes. The ability of other GCD2 and GCD7 mutations (designated class II alleles) to suppress the toxicity of eIF2(␣P) was enhanced by deletion of GCN3. The fact that the phenotypes of the class II GCD2 and GCD7 mutations are additive with gcn3⌬ provides strong evidence that GCD2 and GCD7 contribute to the regulation of eIF2B independently of GCN3.
Previously, we observed numerous allele-specific interactions between mutations in GCD2 and GCN3, which suggested that these two subunits contact one another in eIF2B (6) . We recently provided biochemical evidence confirming that GCD2, GCD7, and GCN3 physically interact with one another and comprise a regulatory domain in eIF2B. Cooverexpression of these three subunits specifically reduced the growthinhibitory effects of eIF2␣ phosphorylation in vivo. The excess subunits present in the overproducing strains were assembled into a stable subcomplex lacking GCD1 and GCD6 that could be immunoprecipitated from yeast cells. Genetic experiments indicated that the overexpressed GCD2-GCD7-GCN3 subcomplex did not possess eIF2-recycling activity, suggesting that it functioned to sequester eIF2(␣P) and rescue the native eIF2B complex from the inhibitor (52) . In addition, formation of this subcomplex did not require the amino-ter- FIG. 9 . Isoelectric-focusing gel electrophoresis of eIF2␣ from GCD2 mutant strains expressing PKR. Derivatives of strain GP3224 (gcd2⌬ gcn2⌬) with the plasmid-borne wild-type or the indicated mutant GCD2 allele and strain H1645 (sui2⌬) with plasmid-borne SUI2 alleles encoding eIF2␣-S51A (p1098) or eIF2␣-L84F (p1350) were transformed with a plasmid encoding PKR (p1420) or the catalytically inactive PKR-K296R allele (p1421). The resulting strains were grown in minimal raffinose medium for 24 h, and galactose was added to induce expression of PKR for an additional 14 hours. Samples of total cellular protein were separated by isoelectric focusing on a one-dimensional vertical slab gel followed by immunoblot analysis with antibodies against eIF2␣. The eIF2␣ antiserum reacts equally well with both the basal and hyperphosphorylated (more acidic) species, as they were raised to a C-terminal fragment of eIF2 lacking Ser-51 (16) . Relevant genotypes are shown, where ϩ indicates the wild-type gene. The percentage of the total eIF2␣ immunoreactivity found in the species phosphorylated on Ser-51 [% 2␣(P)] was determined by quantitative densitometry.
minal half of GCD2, the region lacking sequence similarity with GCD7 and GCN3. Combining these results with the present findings leads us to propose that GCD2, GCD7, and GCN3 constitute a regulatory domain in eIF2B which interacts with eIF2␣ in the region of the phosphorylation site. This provides an explanation for why a single missense mutation in only one of these subunits can abolish the regulatory mechanism (Fig. 2 to 4) . Regions of homology in the three subunits that are largely devoid of regulatory mutations are hydrophobic and so may comprise the structural cores of these proteins or mediate their interactions with other subunits in the eIF2B complex.
Genetic evidence supports the idea that the eIF2B regulatory domain directly interacts with eIF2␣ in the vicinity of Ser-51. It was found that the L84F substitution in eIF2␣, which eliminated the growth-inhibitory effect of phosphorylated eIF2 (46) , also suppressed the impairment of eIF2B function caused by a subset of gcn3 c alleles (47) . As GCN3 is dispensable for catalysis, it is improbable that the gcn3 c alleles directly impair the active site for nucleotide exchange in eIF2B. It seems more likely that they alter the interaction between eIF2 and eIF2B in a way that mimics the inhibitory effect of eIF2(␣P). If so, they may cause nonphosphorylated eIF2 ⅐ GTP to dissociate more slowly from eIF2B, decreasing the amount of eIF2B that is available to bind eIF2 ⅐ GDP. Interestingly, the gcn3 c alleles that are efficiently suppressed by the eIF2␣-L84F substitution (gcn3 c -A26T, gcn3 c -D71N, and gcn3 c -R104K) all map within the N-terminal cluster of Gcn Ϫ alleles in GCN3 described here (Fig. 5) , consistent with the idea that this ca. 70-residue segment of GCN3 directly interacts with eIF2␣.
A model for nucleotide exchange and its inhibition by phosphorylated eIF2. A critical question regarding the mechanism of guanine nucleotide exchange by eIF2B and its inhibition by eIF2(␣P) is whether the regulatory domain of eIF2B constituted by GCD2, GCD7, and GCN3 interacts with both eIF2 and eIF2(␣P). If the regulatory domain of eIF2B interacted only with the inhibitor eIF2(␣P), this would imply the existence of two distinct binding sites for eIF2 on eIF2B, one catalytic and one regulatory. In this model, the substrate eIF2 would have a high affinity for the catalytic site but a low affinity for the regulatory site, while the reverse would be true for the inhibitor, eIF2(␣P). In addition, binding of the inhibitor to the regulatory site would have to prevent either binding or nucleotide exchange of the substrate at the catalytic site. A simpler idea is that eIF2 and eIF2(␣P) bind at the same location on eIF2B, with different eIF2B subunits making distinct contacts with different positions on eIF2. This second hypothesis is more consistent with the identification of eIF2(␣P) as a competitive inhibitor of eIF2B (39) . In our version of this model (Fig. 10) , the GCD2-GCD7-GCN3 regulatory domain forms a surface that contacts the ␣ subunit of eIF2 in the vicinity of the phosphorylation site at Ser-51. GCD1 and GCD6 would interact with the ␥ subunit of eIF2 and contribute most of the residues in the active site that catalyze nucleotide exchange. The interaction between the GCD2-GCD7-GCN3 regulatory domain and the phosphorylated ␣ subunit of eIF2 would prevent nucleotide exchange, either by distorting the catalytic center in eIF2B (Fig. 10B ) or by interfering with proper positioning of the ␥ subunit of eIF2 in the active site.
The regulatory mutations isolated in this study could disrupt key contacts between the regulatory surface formed by GCD2, GCD7, and GCN3 and eIF2␣ which are required to distinguish between phosphorylated and nonphosphorylated eIF2. One possibility is that the mutations decrease the affinity of eIF2B for eIF2(␣P), diminishing its effectiveness as a competitive inhibitor. We disfavor this idea for the GCD2-L381Q and GCD2-K627T mutations because Ͼ80% of the eIF2␣ can be phosphorylated in mutants containing these alleles (Fig. 9) . If the eIF2B in GCD2-L381Q and GCD2-K627TGCD2 mutants cannot utilize eIF2(␣P) as a substrate, then the ability of these mutants to grow normally with more than 80% of their eIF2 phosphorylated implies that less than 20% of the wild-type eIF2 can support a high level of translation initiation. This seems unlikely unless these eIF2B mutations also increase the rate of exchange on nonphosphorylated eIF2 ⅐ GDP. We prefer the simpler explanation that mutant eIF2B complexes in the strains bearing the most effective suppressors have gained the ability to catalyze nucleotide exchange on phosphorylated eIF2. This is shown in Fig. 10C . Consistent with this model, in vitro experiments with mammalian factors have shown that eIF2(␣P) ⅐ GTP can form an active ternary complex with initiator tRNA Met (27) , and this complex can bind to 40S ribosomal subunits (45) . The ability to accept eIF2(␣P) as a substrate could arise from an altered interaction between the GCD2-GCD7-GCN3 regulatory surface and the ␣ subunit of eIF2 that allows proper positioning of the phosphorylated substrate in the active site. Alternatively, the regulatory mutations could prevent interactions between eIF2B subunits needed to distort the active site when eIF2(␣P) is bound (Fig. 10C) .
The model in Fig. 10 has two critical structural features: (i) the use of homologous regions in GCD2, GCD7, and GCN3 to form a single regulatory domain with contacts between these three subunits in eIF2B and (ii) the use of other homologous segments in these proteins to form a surface which interacts with eIF2␣ in regions surrounding the phosphorylation site. While we propose (item ii) that homologous segments in GCD2, GCD7, and GCN3 are involved in the interaction with eIF2␣, it appears that each protein utilizes a distinct set of amino acid positions to carry out its regulatory function. Whereas substitutions at the identical positions in GCN3-S293R and GCD7-S359G both overcome the inhibitory effects of eIF2(␣P) on eIF2B, the corresponding substitution in gcd2-S638R causes a reduction in eIF2B function. Similarly, the GCD7-P291S allele suppresses the effects of eIF2(␣P), but the gcd2-P502S substitution at the corresponding position makes eIF2B hypersensitive to eIF2(␣P). These findings can be explained by proposing that GCD2, GCD7, and GCN3 employ overlapping, but nonidentical, amino acid positions in their homologous domains to make unique contacts with different locations in eIF2␣. It is interesting that similar structural features have been identified by X-ray crystallography of antigenantibody complexes. The light and heavy chains of the antibody molecule interact with one another in regions of sequence similarity between the two chains, and each chain makes specific contacts with the antigen across a continuous surface at the interface between the antigen and antibody (14, 26) . In addition, the recognition of phosphoserine at position 51 in eIF2␣ by eIF2B is a process that may be similar to the recognition of phosphotyrosine by SH2 domains (32, 34) .
PKR has been implicated as a tumor suppressor based on the fact that expression of catalytically defective forms of PKR, which inhibit the endogenous enzyme, transformed NIH 3T3 cells and led to tumor formation in nude mice (28, 31) . It is unclear whether the tumor suppressor activity of PKR involves down-regulation of eIF2 function, as PKR is also involved in transcriptional regulation of NF-B (29) . Support for the idea that inhibition of eIF2 recycling is critical for the tumor suppressor activity of PKR was provided by showing that overexpression of the nonphosphorylatable Ala-51 mutant of eIF2␣ duplicated the phenotypes of expressing catalytically defective PKR (18) . However, these results could be explained by an indirect mechanism whereby overexpression of nonphosphorylatable eIF2␣ leads to the formation of PKR ⅐ eIF2␣ complexes that prevent PKR from phosphorylating other substrates. Introducing mutations in mammalian eIF2B subunits analogous to those described here for the yeast factor may produce eIF2B molecules with reduced sensitivity to eIF2(␣P). This would provide an ideal test to determine whether the tumor suppressor activity described for PKR is mediated by phosphorylation of eIF2␣ and hence inhibition of eIF2B function. FIG. 10 . Model for interactions between eIF2 and eIF2B during guanine nucleotide exchange and inhibition by phosphorylated eIF2. eIF2 (composed of three subunits, ␣, ␤, and ␥) is shown interacting with eIF2B (subunits labelled 7, 2, 3, 6, and 1 representing GCD7, GCD2, GCN3, GCD6, and GCD1, respectively). The ␣ subunit of eIF2 (depicted as an ellipse) contacts the regulatory domain composed of homologous eIF2B subunits GCD7, GCD2, and GCN3 (represented as similarly shaped wedges), along a single interface between the three regulatory subunits of eIF2B and the region of eIF2␣ around serine 51, the site of phosphorylation. The GCD1 and GCD6 subunits are depicted making additional contacts with the ␤ and ␥ subunits of eIF2. (A) We propose that when the ␣ subunit of bound eIF2 is not phosphorylated, this is recognized by the regulatory domain of eIF2B. The eIF2 ⅐ GDP ⅐ eIF2B complex undergoes a hypothetical conformational change in eIF2B (represented here as a shape change in GCD1 and GCD6) which leads to an exchange of GDP for GTP on eIF2. (B) In the presence of eIF2(␣P), phosphoserine at position 51 in the bound eIF2 is detected by direct contacts made between eIF2(␣P) and the eIF2B regulatory domain. These contacts prevent the conformational change in GCD1 and GCD6 required for GDP-GTP exchange on eIF2, such that eIF2(␣P) ⅐ GDP is released unaltered. Biochemical experiments indicate that eIF2(␣P) ⅐ GDP binds eIF2B with higher affinity than does nonphosphorylated eIF2 ⅐ GDP, suggesting that repeated binding and release of eIF2(␣P) ⅐ GDP mediates competitive inhibition of guanine nucleotide exchange (39) . (C) Possible mode of action of eIF2B regulatory mutants to allow guanine nucleotide exchange with phosphorylated eIF2. Mutant eIF2B (eIF2B*), shown here with a GCD2 mutation (2*), alters the interaction between eIF2(␣P) ⅐ GDP and eIF2B in a way that allows guanine nucleotide exchange to proceed. 
